Acevedo Jason L, Shah Rahul K, Brietzke Scott E
Department of Otolaryngology-Head and Neck Surgery, Walter Reed Army Medical Center, Washington, DC, USA.
Otolaryngol Head Neck Surg. 2008 Apr;138(4):418-24. doi: 10.1016/j.otohns.2007.11.018.
Systematically review the published literature regarding the efficacy of nonsurgical therapies in the treatment of head and neck (H&N) lymphatic malformations (LM) in children.
MEDLINE.
MEDLINE was searched for literature relating to nonsurgical treatments for H&N LM.
The initial search returned 1876 articles, with 22 meeting criteria. The majority (20) were case series. All therapies were percutaneous, with OK-432 or bleomycin sclerotherapy being most common. Random-effects modeling revealed 43% (CI = 28.9%-57%) of patients undergoing OK-432 for LM achieved a complete/excellent response, 23.5% (CI = 5.8%-41.3%) achieved a good response, 16.9% (CI = 10.3%-23.4%) achieved a fair/poor response, and 15.4% (CI = 8.6%-22.2%) observed no response. In the bleomycin group, the results were: 35.2% (CI = 15.7%-54.6%) excellent, 37.1% (CI = 22%-52.3%) good, 18.4% (CI = 2.7%-34.2%) fair/poor, and 11.6% (CI = 3.5%-19.6%) no response. Seven major complications were noted out of the 289 patients in the series, including two mortalities.
The literature indicates that sclerotherapy for H&N LM achieves excellent/good clinical response in a majority of patients, with few complications, and anecdotally does not complicate future surgery.
系统回顾已发表的关于非手术疗法治疗儿童头颈部(H&N)淋巴管畸形(LM)疗效的文献。
医学期刊数据库(MEDLINE)。
在医学期刊数据库中检索与H&N LM非手术治疗相关的文献。
初步检索得到1876篇文章,其中22篇符合标准。大多数(20篇)为病例系列研究。所有治疗均为经皮治疗,其中溶链菌制剂OK-432或博来霉素硬化疗法最为常见。随机效应模型显示,接受OK-432治疗LM的患者中,43%(可信区间=28.9%-57%)达到完全/极佳反应,23.5%(可信区间=5.8%-41.3%)达到良好反应,16.9%(可信区间=10.3%-23.4%)达到中等/差反应,15.4%(可信区间=8.6%-22.2%)无反应。在博来霉素组,结果如下:35.2%(可信区间=15.7%-54.6%)极佳,37.1%(可信区间=22%-52.3%)良好,18.4%(可信区间=2.7%-34.2%)中等/差,11.6%(可信区间=3.5%-19.6%)无反应。该系列289例患者中记录到7例主要并发症,包括2例死亡。
文献表明,H&N LM硬化疗法在大多数患者中取得了极佳/良好的临床反应,并发症较少,且据经验不会使未来手术复杂化。